NEW YORK , June 1, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Osiris Therapeutics, Inc. ("Osiris" or the "Company") (NasdaqGM: OSIR -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at

info@bgandg.com or 212-697-6484.

The investigation concerns whether Osiris and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934

On May 27, 2016, after the market closed, the Company announced that it was advised by the United States Attorney's Office for the Southern District of New York that the office had opened a criminal investigation into the Company. Osiris also announced that it understands the investigation to relate to previously disclosed matters also under investigation by the SEC.

Following this news, Osiris stock fell $0.65 or 11.73% to close at $5.01 on May 31, 2016.

If you are aware of any facts relating to this investigation, or purchased shares of Osiris, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-osiris-therapeutics-inc-300277328.html

SOURCE Bronstein, Gewirtz & Grossman, LLC